Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 683

1.

Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.

Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):475-82. doi: 10.1093/jnci/djn058. Epub 2008 Mar 25. Erratum in: J Natl Cancer Inst. 2008 May 7;100(9):685. Maenpa, Johanna [corrected to Maenpaa, Johanna].

PMID:
18364505
2.

Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.

von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group.

J Natl Cancer Inst. 2005 Apr 6;97(7):533-5.

PMID:
15812079
3.

Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.

Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE.

J Natl Cancer Inst. 2005 Apr 20;97(8):595-602.

PMID:
15840882
4.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
5.

Menopausal hormone therapy (HT) in patients with breast cancer.

Batur P, Blixen CE, Moore HC, Thacker HL, Xu M.

Maturitas. 2006 Jan 20;53(2):123-32. Review.

PMID:
16368466
6.

Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.

Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE.

J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9. doi: 10.1093/jnci/djn394. Epub 2008 Dec 9.

PMID:
19066271
7.

Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.

Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL.

J Natl Cancer Inst. 2008 Apr 16;100(8):563-71. doi: 10.1093/jnci/djn075. Epub 2008 Apr 8. Erratum in: J Natl Cancer Inst. 2008 May 21;100(10):754.

PMID:
18398105
8.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
9.

A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy.

Marttunen MB, Hietanen P, Pyrhönen S, Tiitinen A, Ylikorkala O.

Maturitas. 2001 Sep 28;39(3):217-25.

PMID:
11574181
10.

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, Cronin W, Wickerham DL.

J Natl Cancer Inst. 2004 Dec 1;96(23):1762-9. Erratum in: J Natl Cancer Inst. 2005 Jan 5;97(1):71.

PMID:
15572758
11.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

12.

Unopposed estrogen therapy and the risk of invasive breast cancer.

Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA.

Arch Intern Med. 2006 May 8;166(9):1027-32.

PMID:
16682578
13.

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.

Lyytinen H, Pukkala E, Ylikorkala O.

Obstet Gynecol. 2009 Jan;113(1):65-73. doi: 10.1097/AOG.0b013e31818e8cd6.

PMID:
19104361
14.

Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy.

Durna EM, Heller GZ, Leader LR, Sjoblom P, Eden JA, Wren BG.

Climacteric. 2004 Sep;7(3):284-91.

PMID:
15669553
15.

Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.

Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE.

J Natl Cancer Inst. 2007 Mar 7;99(5):365-75.

PMID:
17341728
16.

Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.

[No authors listed]

Prescrire Int. 2004 Jun;13(71):106-9.

PMID:
15233153
17.

Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.

Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE, Blaakaer J.

Arch Intern Med. 2004 Nov 8;164(20):2253-9.

PMID:
15534163
18.

Hormone therapy and breast cancer: what factors modify the association?

Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG.

Menopause. 2006 Mar-Apr;13(2):178-84.

PMID:
16645531
19.

Estrogen replacement therapy in patients with early breast cancer.

Natrajan PK, Gambrell RD Jr.

Am J Obstet Gynecol. 2002 Aug;187(2):289-94; discussion 294-5.

PMID:
12193914
20.

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E.

Eur J Cancer. 2013 Jan;49(1):52-9. doi: 10.1016/j.ejca.2012.07.003. Epub 2012 Aug 11.

PMID:
22892060

Supplemental Content

Support Center